S09.F - Sutro Biopharma, Inc.
| Previous Close | 4.6800 |
| Open | 4.6400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.6400 - 4.6400 |
| 52 Week Range | 3.2000 - 7.9000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 280.334M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three years
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders should be happy to see the share price up 15% in the last month...
- Zacks
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Investors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) Tunnel
With a price-to-sales (or "P/S") ratio of 3.9x Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be sending very bullish...
- Zacks
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this year
Looking at Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) insider transactions over the last year, we can see that insiders...
- Simply Wall St.
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
- Simply Wall St.
With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...
- Simply Wall St.
Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 54% over the last year
While it may not be enough for some shareholders, we think it is good to see the Sutro Biopharma, Inc. ( NASDAQ:STRO...
- Simply Wall St.
Need To Know: Analysts Are Much More Bullish On Sutro Biopharma, Inc. (NASDAQ:STRO) Revenues
Shareholders in Sutro Biopharma, Inc. ( NASDAQ:STRO ) may be thrilled to learn that the analysts have just delivered a...
- Zacks
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%
The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Simply Wall St.
Sutro Biopharma Third Quarter 2022 Earnings: Misses Expectations
Sutro Biopharma ( NASDAQ:STRO ) Third Quarter 2022 Results Key Financial Results Revenue: US$25.1m (up 195% from 3Q...
- Zacks
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks
Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Simply Wall St.
A Sutro Biopharma, Inc. (NASDAQ:STRO) insider increased their holdings by 4.3% last year
From what we can see, insiders were net buyers in Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) during the past 12 months...
- Zacks
bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.
- Zacks
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%
The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks
Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Simply Wall St.
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)
Celebrations may be in order for Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders, with the analysts delivering a...
- Zacks
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
